IL22 and cardiac hypertrophy: Although clinical data have demonstrated that compared to the control group, higher serum IL-22 levels were observed in CHF patients with an NYHA class of II and III [14], the involvement of IL-22 in cardiac hypertrophy is still unknown, and the pathogenesis remains to be clarified.